Sure, technology is all the rage these days. Dot-coms, optics, networkers, software and wireless companies dominate our thinking. But there's intensity in other quadrants, too.

For instance, biotechnology is making all kinds of noise. (OK, so it's a kind of technology, but at least it starts with a different syllable.) After a rollicking start earlier this year, the sector has been reeling. We know you're eager for more information, and that's why we've added to our biotech coverage. Recent arrival

Dane Hamilton

is already weighing in on the sector. As with other important sectors, we're focused on giving you an information edge: scoops, analysis and insight.

Also, I'd like to point out a couple of things from the weekend that you might have overlooked. First, there's an excellent interview with

J.P. Morgan


Doug Cliggott

. It's an in-depth look at what Cliggott is thinking about these days, including his favorite stocks and his views on the market. In addition, you should take time to check out the stories from our Personal Finance Saturday section, including a tax deduction guide from our in-house tax expert,

Tracy Byrnes


Herb Greenberg's

"Tips for the Timid" is another winner.

You should also check out

James J. Cramer's

rewrite of "The Trading Goddess' 10 Commandments." It's one more sign that Cramer gives you the real dope from the trading turret like nobody else. He's been firing on all cylinders lately, and we at

TheStreet Recommends

salute him for his recent honor as one of the 100 most influential financial journalists of the century as recognized by


, an organization that covers the financial media. This week you can get up close and personal with Cramer when he chats on



. At 5 p.m. ET on Wednesday he'll take questions from all comers. It's free, but you have to register at

As ever, if you've got issues or concerns, feel free to shoot me an email at or contact our able customer support staff at We'll make sure your issues get addressed.

Have a great week!

L'Etoile du Nord

Dave Kansas


Dave Kansas is editor-in-chief of In keeping with TSC's editorial policy, he doesn't own or short individual stocks, though he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. He welcomes your feedback at